million people affected worldwide

Current Treatments

Psychedelic research currently is in Preclinical

Highlighted Institutes

These are the institutes, from companies to universities, who are working on Treatment-Resistant Depression.

Revixia Life Sciences

Revixia Life Sciences is a biotech company developing Salvinorin A (salvia) for substance use disorders (SUD), treatment-resistant depression (TRD), and pain.

Highlighted People

These are some of the best-known people, from researchers to entrepreneurs, working on Treatment-Resistant Depression.

George Goldsmith

George Goldsmith is the CEO, Co-Founder, and Chairman of Compass Pathways, which he has led since July 2016.

Linked Research Papers about Treatment-Resistant Depression

Arketamine, a new rapid-acting antidepressant: A historical review and future directions

Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression

Increased low-frequency brain responses to music after psilocybin therapy for depression

Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use

Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression

Do sleep changes mediate the anti-depressive and anti-suicidal response of intravenous ketamine in treatment-resistant depression?

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

The relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression

Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression

Ketamine for the treatment of major depressive disorder and bipolar depression: A review of the literature

Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression

Response to Intravenous Racemic Ketamine After Switch From Intranasal (S)-ketamine on Symptoms of Treatment-Resistant Depression and PTSD in Veterans: a Retrospective Case Series

Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

Adverse Events and Measurement of Dissociation after the First Dose of Esketamine in Patients with TRD

Repeated intranasal ketamine for treatment-resistant depression – the way to go? Results from a pilot randomised controlled trial

Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment

Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression

Effects of psilocybin therapy on personality structure

A Single Dose Of Ayahuasca Modulates Salivary Cortisol In Treatment-Resistant Depression

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression

Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing

Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans

Clinical Effectiveness of Intravenous Racemic Ketamine Infusions in a Large Community Sample of Patients With Treatment-Resistant Depression, Suicidal Ideation, and Generalized Anxiety Symptoms: A Retrospective Chart Review

Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability

Ketamine and Attentional Bias Toward Emotional Faces: Dynamic Causal Modeling of Magnetoencephalographic Connectivity in Treatment-Resistant Depression

Low-dose ketamine for treatment resistant depression in an academic clinical practice setting

Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review

Frequency analysis of symptomatic worsening following ketamine infusions for treatment resistant depression in a real-world sample: Results from the canadian rapid treatment center of excellence

Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and efficacy (REAL-ESK study)

Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study

Depression, Estrogens, and Neuroinflammation: A Preclinical Review of Ketamine Treatment for Mood Disorders in Womens

Treating Bipolar Depression with Esketamine: Safety and Effectiveness data from a naturalistic multicentric study on Esketamine in Bipolar versus Unipolar Treatment-Resistant Depression

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis

The Impact of Childhood Maltreatment on Intravenous Ketamine Outcomes for Adult Patients with Treatment-Resistant Depression

Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement

Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study

Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression

Low-dose ketamine for treatment resistant depression in an academic clinical practice setting

Nitrous Oxide: an emerging novel treatment for treatment-resistant depression

Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression

Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies

Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial

Long-Term Efficacy of Combination Therapy of Transcranial Magnetic Stimulation with Ketamine for Patients with Treatment-Resistant Depression

Treatment of a Complex Personality Disorder Using Repeated Doses of LSD-A Case Report on Significant Improvements in the Absence of Acute Drug Effects

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design